All In Biotech

Drug Trial Radar · NCT04367883

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-CoV2 Infection

Last checked: Nov 20, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

3,000

Planned (sponsor's estimate)

Start

Mar 1, 2020

Primary completion

Jan 19, 2025

Study completion Feb 24, 2028

Sponsor

Lead sponsor
Consorci Sanitari de TerrassaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina; Institut Català de la Salut
First posted
Apr 29, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.

Conditions

  • COVID19
  • Influenza Vaccination
  • ACE Inhibitors
  • ARB
  • Antihistamine Allergy
  • Amantadine

Interventions

  • AntihistamineDrug

    No intervention is performed. We propose an observational study.

  • AmantadineDrug

    No intervention is performed. We propose an observational study

  • ACEIDrug

    No intervention is performed. We propose an observational study.

  • ARBDrug

    No intervention is performed. We propose an observational study.

  • Influenza vaccine and COVIDOther

    No intervention is performed. We propose an observational study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. hospital outputTime frame: from March 1, 2020.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital de Terrassa

    Terrassa, Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.